Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6964MR)

This product GTTS-WQ6964MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6964MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8288MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ8414MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10381MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ9389MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12277MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ295MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ3218MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ795MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW